Quantitative relationship between infliximab exposure and inhibition of C‐reactive protein synthesis to support inflammatory bowel disease management
Open Access
- 12 November 2020
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 87 (5) , 2374-2384
Abstract
Aim Quantitative and kinetic insights into drug exposure‐disease response relationship might enhance our knowledge on loss of response and support a more effective monitoring of inflammatory activity by biomarkers in patients with inflammatory bowel diseases treated with infliximab. This study aimed to derive recommendations for dose adjustment and treatment optimisation based on mechanistic characterisation of the relationship between infliximab serum concentration and C‐reactive protein (CRP) concentration. Methods Data from an investigator‐initiated trial included 121 patients with IBD during infliximab maintenance treatment. Serum concentrations of infliximab, anti‐drug antibodies (ADA), CRP, and disease‐related covariates were determined at the mid‐term and end of a dosing interval. Data were analysed using a pharmacometric nonlinear mixed‐effects modelling approach. An infliximab exposure‐CRP model was generated and applied to evaluate dosing regimens to achieve CRP remission. Results The generated quantitative model showed that infliximab has the potential to inhibit up to 72% (9% RSE) of CRP synthesis in a patient. Infliximab concentration leading to 90% of the maximum CRP synthesis inhibition was 18.4 μg/mL (43% RSE). Presence of ADA was the most influential factor on infliximab exposure. With standard dosing strategy, ≥55% of ADA+ patients experienced CRP nonremission. Shortening the dosing interval and co‐therapy with immunomodulators were found to be most beneficial to maintain CRP remission. Conclusions With the generated model we could for the first time establish a robust relationship between infliximab exposure and CRP synthesis inhibition, that could be utilized for treatment optimisation in IBD patients.Keywords
This publication has 29 references indexed in Scilit:
- Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serumJournal of Immunological Methods, 2012
- C‐reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post‐hoc analysis from ACCENT IAlimentary Pharmacology & Therapeutics, 2012
- Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is StoppedGastroenterology, 2012
- Pharmacokinetic Properties of Infliximab in Children and Adults with Crohn's Disease: A Retrospective Analysis of Data from 2 Phase III Clinical TrialsClinical Therapeutics, 2011
- Levels of C-reactive Protein Are Associated With Response to Infliximab Therapy in Patients With Crohn's DiseaseClinical Gastroenterology and Hepatology, 2011
- Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects ModelsThe AAPS Journal, 2011
- Population pharmacokinetic analysis of infliximab in patients with ulcerative colitisEuropean Journal of Clinical Pharmacology, 2009
- Infliximab Pharmacokinetics in Inflammatory Bowel Disease PatientsTherapeutic Drug Monitoring, 2008
- Laboratory markers in IBD: useful, magic, or unnecessary toys?Gut, 2006
- Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease.Journal of Clinical Investigation, 1993